VectorB2B is @ EIC Service Catalogue
We are part of the EIC Service Catalogue, supporting beneficiaries in both preclinical and clinical development
News
Stay ahead with the latest in R&D, clinical trials & scientific trends
Highlights
A new Clinical Trial for Acute Spinal Cord Injury in Spain and Portugal
VectorB2B is managing Technophage Ph 1b/2a Clinical Trial of TZ-161 for Acute Spinal Cord Injury – Portugal and Spain
VectorB2B at Business Portugal magazine
We are pleased to share our participation in the June/July edition of Business Portugal magazine, where our Co-CEOs, Ana Custódio and Francisco Castro, highlight the journey of VectorB2B as a center of innovation in health.
The only in vivo TOX GLP certified facility in Portugal
VectorB2B design and execute your preclinical GLP/ non-GLP toxicology studies, ensuring the success of your drug/health product development program while meeting global standards and specifications for quality and compliance
MICROBIOTEC’25
Join us
@ University of Azores, Ponta Delgada, Portugal
4-6 December 2025
EATRIS Spotlight Programme “ATMP Summit: The importance of advanced therapies in today’s context”
VectorB2B was part of this event.
@ Instituto Pedro Nunes (IPN), Coimbra, Portugal
17 November 2025
5th Meeting of the Portuguese Society of Hernia and Abdominal Wall: “Building Foundations for Stronger Walls”
VectorB2B was part of this event.
@ Évora, Portugal
13-14 November 2025
17th Annual Protein & Antibody Engineering Summit (PEGS) Europe
VectorB2B was part of this event.
@ Lisbon Congress Center, Portugal
11-13 November 2025
IX National Congress of Entrepreneurial Scientists
VectorB2B was part of this event.
@ Santiago de Compostela, Spain
2-3 October 2025
Biomeet 2025
VectorB2B was part of this event
@ Taguspark Conference Center Oeiras, Portugal
29-30 September 2025
A new Partnership with SmartBio Analytics
We’re proud to announce a new partnership with SmartBio Analytics, marking the beginning of a promising collaboration in the field of preclinical and clinical research.